Business
Capital Markets Day Notification
Capital Markets Day Notification.
About this update from Avacta Group Plc
[{"type":"text","content":"\n \nRNS Number : 7710A Avacta Group PLC 08 January 2018 \n\n \n \n8 January 2018\n \nAvacta Group plc\n \n(\"Avacta\", \"the Group\" or \"the Company\")\n \nCapital Markets Day Notification\n \n \nAvacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, today announces that it will host a Capital Markets Day for financial analysts and institutional investors on Wednesday, 7 February 2018 from 2pm to 4pm at finnCap's offices, 60 New Broad St, London, EC2M 1JJ.\nThe event will begin with a non-technical corporate update by Alastair Smith, Chief Executive Officer on strategy, key technical milestones and value inflection points and emerging themes within the business.\nFollowing this update there will also be an opportunity to speak with other members of the Senior Management Team, whilst refreshments are served.\nNo new material information will be disclosed during the event. \n If you would like to attend, please contact [email protected].\nThe presentation materials will be made available on the Group's website www.avacta.com\n- Ends -\n \nFor further information from Avacta Group plc, please contact:\n \n\n\n\n\nAvacta Group plc\nAlastair Smith, Chief Executive Officer\nTony Gardiner, Chief Financial Officer\n \n\n\nTel: +44 (0) 844 414 0452\nwww.avacta.com \n\n\n\n\nfinnCap Ltd\nGeoff Nash / Giles Rolls - Nominated Adviser\nTim Redfern / Alice Lane / Nikita Jain - Corporate Broking\n \nWG Partners\nNigel Birks / Nigel Barnes\nDavid Wilson / Claes Spang\n \n\n\nTel: +44 (0) 207 220 0500\nwww.finncap.com\n \n \nTel: +44 (0) 203 705 9318\nTel: +44 (0) 203 705 9217\nwww.wgpartners.co.uk\n \n\n\n\n\nZyme Communications (Trade and Regional Media)\nKatie Odgaard\n \n \nYellow Jersey PR (Financial Media and IR)\nSarah Hollins\n\n\nTel: +44 (0)7787 502 947\[email protected] \n \n \nTel: +44 (0)7764 947137\[email protected]\n \n\n\n\n\n \nAbout Avacta Group plc (www.avacta.com)\nAvacta's principal focus is on its proprietary Affimer® technology which is a novel engineered alternative to antibodies that has wide application in Life Sciences for diagnostics, therapeutics and general research and...